Furuya, Naoki
St. Marianna University School of Medicine
3 papers on CoChatORCID 0000-0001-7162-5946
Most cited papers
- Verified
Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations: NEJ026
Furuya, N., Fukuhara, T., Saito, H., Watanabe, K., Sugawara, S., Iwasawa, S., Tsunezuka, Y., Yamaguchi, O., Okada, M., Yoshimori, K., et al. (2018) · Journal of Clinical Oncology
Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment
Cited by 59
- Verified
Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834
Miura, S., Tanaka, H., Misumi, T., Yoshioka, H., Tokito, T., Fukuhara, T., Sato, Y., Shiraishi, Y., Naoki, K., Akamatsu, H., et al. (2025) · Journal of Clinical Oncology
Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment
Cited by 37
- Verified
AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells
Morimoto, K., Yamada, T., Hirai, S., Katayama, Y., Fukui, S., Sawada, R., Tachibana, Y., Matsui, Y., Nakamura, R., Ishida, M., et al. (2024) · Cancer Letters
Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling
Cited by 20
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free